We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Test Identifies Pregnant Women at Risk for Preeclampsia

By Labmedica staff writers
Posted on 26 Mar 2008
A test that identifies pregnant women at risk of developing preeclampsia is performed from as early as the seventh week of pregnancy, and it predicts the appearance of the condition six months later. More...
The test results provide the physician with a useful tool to evaluate the surveillance and management of the pregnant woman.

According to the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA), preeclampsia affects 5-7% of all pregnant women and represents a serious challenge for obstetricians, and prenatal and diagnostic laboratories. This disorder can result in loss of life; blindness; motor and mental disorders or premature newborns; pregnancy hypertension; and kidney, liver, and cardiovascular malfunctioning. It is a rapidly progressive condition characterized by sudden hypertension and an elevated protein level in urine.

Scientists from Diagnostic Technologies (Yokne'am Illit, Israel) developed a breakthrough technology that could help doctors identify pregnant women at risk of developing preeclampsia. The early detection is performed about 20 weeks before symptoms develop, and is based on the use of a simple blood test, which determines the level of a protein produced by the placenta--placenta protein 13 (PP13).

"Preeclampsia is the second most frequent cause of maternal death in pregnancy, but to our disappointment the dimension of the problem is not known to the public. Many women, pregnant or not, are unaware of the real risk,” said developmental neurobiologist Dr. Hamutal Meiri, CEO of Diagnostic Technologies. Early detection gives rise to prevention and management of the risk due to better pregnancy management and preventive treatment.”

The company is now working towards completing a study of the test with the aim of achieving U.S. Food and Drug Administration (FDA; Rockville, MD, USA) approval. Dr. Meiri said that they plan to complete development of a product dedicated to tailor medication to women at high risk for preeclampsia, and to identify families with a genetic disorder that predisposes to preeclampsia.


Related Links:
U.S. Centers for Disease Control and Prevention
Diagnostic Technologies
U.S. Food and Drug Administration

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.